<a id='225e3420-d6a6-4765-8cca-f34797da05d6'></a>

Components of PN

<a id='182251f5-0f7a-4fe7-a020-58d3e1f42a12'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='7f218b6b-dfd5-41d9-9fa9-1c04c8f88617'></a>

CAPTION ERROR

<a id='c5903626-47a4-4335-8b4f-db79cd2644b4'></a>

Typical Nutritional Components of PN

<a id='9e82c334-48a8-4843-83e3-8c07bc221127'></a>

Water

Macronutrients
* Protein
* Carbohydrate
* Fat

<a id='fc44e57b-a056-4e69-87c4-cacb0d5c4736'></a>

# Micronutrients
* Electrolytes & Minerals
* Vitamins
* Trace elements

<a id='81775902-4433-4fc1-900c-9d3721b93f31'></a>

# Other additives

*   Heparin
*   Cysteine
*   Carnitine
*   Medications (e.g., famotidine, insulin)

<a id='a213f230-3d50-45ab-99bb-c19c09096169'></a>

<::NASPGHAN FOUNDATION logo with a blue gradient background.: figure::>

<a id='b01c9d69-150e-4034-bcd6-b22386b52d46'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the text "NASPGHAN" in dark blue, bold, italicized font on a light blue gradient background with a dark blue curved line underneath.::>

<a id='2931d8c3-e404-4045-8a8b-f2a6be970fa2'></a>

# PN Macronutrients

*   Three major macronutrients
    *   Carbohydrates (Dextrose)
    *   Fat (Intravenous Lipid Emulsion - ILE)
    *   Protein (Amino Acids - AA)

*   Macronutrients may be combined in PN solution as follows
    *   2-in-1: Dextrose + AA (lipids administered separately)
    *   3-in-1: Dextrose + AA + Lipids

<a id='e9f1734a-786a-402f-b1d3-8ecc77801405'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='55d77f7b-e231-4c47-8208-e9225f4a83e1'></a>

CAPTION ERROR

<a id='a4cdc2d2-76b2-48cd-862a-b4b7d8789c87'></a>

Components of PN:
Macronutrient Guidelines - Infants

<a id='f88cb5e5-3abc-48bf-a4eb-d8c2e30c54e0'></a>

<table id="3-1">
<tr><td id="3-2">Infants (< 1 yr)</td><td id="3-3" colspan="2">Initiation</td><td id="3-4" colspan="2">Advance By</td><td id="3-5" colspan="2">Goals</td></tr>
<tr><td id="3-6"></td><td id="3-7">Preterm</td><td id="3-8">Term</td><td id="3-9">Preterm</td><td id="3-a">Term</td><td id="3-b">Preterm</td><td id="3-c">Term</td></tr>
<tr><td id="3-d">Protein (g/kg/day)*</td><td id="3-e">1 – 3 (3 – 4 max)</td><td id="3-f">2.5 – 3</td><td id="3-g">–</td><td id="3-h">–</td><td id="3-i">3 – 4</td><td id="3-j">2.5 – 3</td></tr>
<tr><td id="3-k">Dextrose (mg/kg/min)</td><td id="3-l">6 – 8</td><td id="3-m">6 – 8</td><td id="3-n">1 – 2</td><td id="3-o">1 – 2</td><td id="3-p">10 – 14 (max 14 – 18)</td><td id="3-q">10 – 14 (max 14 – 18)</td></tr>
<tr><td id="3-r">ILE (g/kg/day)**</td><td id="3-s">0.5 – 1</td><td id="3-t">0.5 – 1</td><td id="3-u">0.5 – 1</td><td id="3-v">0.5 – 1</td><td id="3-w">3 (max 0.15 g/kg/hr)</td><td id="3-x">2.5 – 3 (max 0.15 g/kg/hr)</td></tr>
</table>
*Protein can be initiated at goal. **ILE doses based on soybean oil emulsion.

<a id='0811fc62-8bd9-47b2-9072-4ded95afd745'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='0a937892-6961-4dc6-9288-91dfdf84a5b8'></a>

Corkins MR, et al. The A.S.P.E.N. Pediatric Nutrition Support Core Curriculum, 2nd Ed. ASPEN; 2015.

<a id='1e2308a9-4712-4329-8e9b-872a78f505f1'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the bold, italicized, dark blue text "NASPGHAN" on a blue gradient background, with a dark blue curved line sweeping underneath the text.::>

<a id='82536401-3a69-4e26-aac6-5fc2303f3bfa'></a>

Components of PN:
Macronutrient Guidelines - Children

<a id='943d67d7-6204-4e0c-80b4-3f256db0c40c'></a>

<::Children (1-10 yr) | Initiation | Advance By | Goals
---|---|---|---
Protein (g/kg/day) | 1.5-2.5 | - | 1.5-2.5
Dextrose (mg/kg/min) | 3-6 | 1-2 | 8-10
ILE (g/kg/day)** | 1-2 | 0.5-1 | 2-2.5
: table::>

<a id='ce017f71-fdfa-41e0-a78b-32d0768e77aa'></a>

**ILE doses based on soybean oil emulsion.

<a id='1c326963-0080-486f-83a0-f9830ba88b17'></a>

<::NASPGHAN
FOUNDATION
: figure::>

<a id='488ce082-2e3c-4f13-981e-0f678339ba59'></a>

Corkins MR, et al. The A.S.P.E.N. Pediatric Nutrition Support Core Curriculum, 2nd Ed. ASPEN; 2015.

<a id='43911d1e-e71c-4907-97d2-68aa0ee00eee'></a>

CAPTION ERROR

<a id='48c43b42-ec1a-4431-96f7-08d69154befa'></a>

Components of PN:
Macronutrient Guidelines – Adolescents

<a id='77bc549d-9e8d-4e94-81d8-c1ca6d2fc34c'></a>

<::table
| Adolescents | Initiation | Advance By | Goals |
|---|---|---|---|
| Protein (g/kg/day) | 0.8 – 2 | – | 0.8 – 2 |
| Dextrose (mg/kg/min) | 2.5 – 3 | 1 – 2 | 5 – 6 |
| ILE (g/kg/day)** | 1 | 1 | 1 – 2 |
: table::>

<a id='23be053f-82ba-45f9-aad2-8ca0350d4f90'></a>

**ILE doses based on soybean oil emulsion.

<a id='85e53ecd-09ad-4ab2-9672-5a1449f1242c'></a>

<::NASPGHAN
FOUNDATION
: figure::>

<a id='2ba9bbef-70d5-4d66-8860-2fa0cb33b04c'></a>

Corkins MR, et al. The A.S.P.E.N. Pediatric Nutrition Support Core Curriculum, 2nd Ed. ASPEN; 2015.

<a id='9694bfc6-8312-484a-b865-609e6e0d0361'></a>

CAPTION ERROR

<a id='838a9f9d-525a-49dc-b630-7226896294f0'></a>

## Macronutrients: Carbohydrates

*   Dextrose (D-glucose monohydrate) is the primary carbohydrate
    *   Monohydrate form provides 3.4 kcal/g
    *   Enteral carbohydrates provide approximately 4 cal/g
*   Typically, 40-55% of caloric intake comes from dextrose
*   Intravenous dextrose must be slowly introduced to allow appropriate endogenous insulin response
*   Toxicity
    *   Hyperglycemia, glucosuria and osmotic diuresis

<::Chemical structure diagram of D-glucose (dextrose) with labeled carbons and hydroxyl groups.: figure::>

*   Glucose provision typically expressed as % dextrose

<a id='cca663fd-2202-46f2-bd08-bde9b874344d'></a>

NASPGHAN
FOUNDATION

<a id='577302af-522c-4c77-8d6d-95fe9c45cb5c'></a>

CAPTION ERROR

<a id='010f4fd6-f6d5-418d-83cb-8122fe41d3a5'></a>

# Glucose Infusion Rate (GIR)

* GIR needs vary with age of patient
* GIR (mg/kg/min) = (Dextrose (g/dL) x Infusion Rate (mL/hr) x 0.167)/wt(kg)
* Typical glucose oxidation rate under most circumstances = 7-13mg/kg/min
  * Beyond this, fat synthesis increases leading to increased respiratory quotient (RQ: CO₂/O₂)
  * In the presence of pulmonary disease, large energy intake may lead to CO₂ retention
* Glucose oxidation rate changes with GIR based on age
  * Neonates, infants: 12.5 mg/kg/min
  * Children, adolescents: 6 mg/kg/min

<a id='d69cf760-ceb9-460d-ae59-3f4a84df1d06'></a>

NASPGHAN
FOUNDATION

<a id='da279c03-dcd8-4bfa-b743-098985cf18bf'></a>

Bresson JL, et al. Pediatr Res. 1989;25(6):645-48.

<a id='22b62437-82c0-4bff-ba38-efe816e68233'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features dark blue, bold, italicized text "NASPGHAN" on a blue gradient background, with a dark blue curved swoosh underneath.::>

<a id='fa7bd30a-b94d-4f87-96c0-415305431941'></a>

GIR – Cont'd
---
* Multiple online calculators exist
* Online tools may allow calculation of total GIR across multiple infusions with different dextrose concentrations
  (i.e., dextrose-containing fluids + PN + compounded medication solutions)
* www.nicutools.org (“glucose delivery”)

<a id='62c73cfd-de77-4d05-afbe-8f395eb568e7'></a>

<::NASPGHAN FOUNDATION logo::>

<a id='79eb2a3c-2d92-441c-8c59-274e4af57208'></a>

CAPTION ERROR

<a id='b3139800-8dcd-4d35-ac25-99f9ecc000b9'></a>

CAPTION ERROR

<a id='28acd610-ccd2-40f0-8674-8666dd0ef843'></a>

Macronutrients:
Dextrose / GIR Minimum Requirements

<a id='6b56d8a2-83d2-4b25-b747-827763ba6ebd'></a>

<::Minimum Dextrose Requirements Based On Age
| Age | GIR (mg/kg/min) | g/kg/day |
|:---|:---|:---|
| Newborn | 7.9 | 11.5 |
| Children | 4.7 | 6.8 |
| Adolescents | 1.9 | 2.7 |
| Adult | 1.0 | 1.4 |
: table::>

<a id='5bda5411-65c9-48c9-bc58-73dd55734354'></a>

- These are the estimated minimum dextrose intakes to meet energy needs of the brain and other glucose-dependent organs
- If patients develop persistent hyperglycemia (>180mg/dL) at these minimum levels, consider providing insulin therapy based on GIR instead of further reduction of dextrose concentration

<a id='ef45ba2a-0515-4e1b-b515-803b42015944'></a>

<::NASPGHAN FOUNDATION logo::>

<a id='21feb5c3-a822-40c8-bf3f-0fd533461706'></a>

Corkins MR, et al. The A.S.P.E.N. Pediatric Nutrition Support Core Curriculum, 2nd Ed. ASPEN; 2015.
Jones MO, et al. J Pediatr Surg. 1993;28(9):1121-25.

<a id='d60fdc83-8e02-4e01-ab71-f43ff9ea7d48'></a>

CAPTION ERROR

<a id='2d180e39-f833-4090-9080-df9f4b3e2594'></a>

# Macronutrients: Protein

* Major physiological functions of protein
  * Structure (i.e., muscle)
  * Function (i.e., enzymes, transport proteins)
  * Nitrogen donor to other compounds (i.e., nucleic acids, carnitine, taurine)
* Protein should not be considered a main energy source
* Protein requirements vary by age and disease state

<a id='0540729b-89cb-4bfb-9f65-0c3d32b35edd'></a>

<::NASPGHAN FOUNDATION logo::>

<a id='b1c61641-4a50-4db2-af2b-a75ec83dbb40'></a>

Kashyap S. Curr Opin Pediatr. 2008;20(2):132-36.

<a id='20b156f3-8d4a-4e76-9a72-6ec9351f9810'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features dark blue, bold, italicized text "NASPGHAN" on a light blue to white gradient background, with a dark blue curved line beneath it.::>

<a id='d7f2e7e0-7c51-49dd-ac3b-c6bb4907885d'></a>

Macronutrients: Amino Acid (AA) Solutions

* Infant protein needs
* Conditional AA needed: histidine, taurine, cysteine
  * Immature synthetic abilities
  * Cysteine added in infants < 1 kg to improve nitrogen balance
    * Also decreases PN solution pH, allowing more calcium and phosphate to be added
* Infant AA solutions are modelled off the serum AA patterns seen in breastfed infants
  * Further study of infant AA requirements ongoing
* Excess protein intake leads to azotemia (elevated blood urea nitrogen, other compounds in blood)

<a id='bec57dea-cf04-49da-888e-e0d6ee799161'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='2c12e91a-70c6-42f8-9686-fb661be16307'></a>

Kashyap S. Curr Opin Pediatr. 2008;20(2):132-36.

<a id='40d75fab-fcf6-4637-8cdd-b75adc352648'></a>

CAPTION ERROR

<a id='ee4e7594-7035-429b-b978-8a020aae4450'></a>

Examples of AA Solutions (per 100 mL)

<a id='7a171df7-8eb8-4453-97dc-1119282712e4'></a>

<table id="12-1">
<tr><td id="12-2"></td><td id="12-3">Amino acid</td><td id="12-4">Aminosyn II®</td><td id="12-5">Novamine® 10%</td><td id="12-6">Premasol® 10%</td><td id="12-7">Trophamine® 10%</td><td id="12-8">Aminosyn® PF</td><td id="12-9">Travasol®</td></tr>
<tr><td id="12-a" rowspan="8">Essential</td><td id="12-b">Isoleucine (g)</td><td id="12-c">0.72</td><td id="12-d">0.6</td><td id="12-e">0.82</td><td id="12-f">0.82</td><td id="12-g">0.76</td><td id="12-h">0.6</td></tr>
<tr><td id="12-i">Leucine (g)</td><td id="12-j">0.94</td><td id="12-k">0.73</td><td id="12-l">1.4</td><td id="12-m">1.4</td><td id="12-n">1.2</td><td id="12-o">0.73</td></tr>
<tr><td id="12-p">Lysine (g)</td><td id="12-q">0.72</td><td id="12-r">0.58</td><td id="12-s">0.82</td><td id="12-t">0.82</td><td id="12-u">0.677</td><td id="12-v">0.58</td></tr>
<tr><td id="12-w">Methionine (g)</td><td id="12-x">0.40</td><td id="12-y">0.40</td><td id="12-z">0.34</td><td id="12-A">0.34</td><td id="12-B">0.18</td><td id="12-C">0.40</td></tr>
<tr><td id="12-D">Phenylalanine (g)</td><td id="12-E">0.44</td><td id="12-F">0.56</td><td id="12-G">0.48</td><td id="12-H">0.48</td><td id="12-I">0.427</td><td id="12-J">0.56</td></tr>
<tr><td id="12-K">Threonine (g)</td><td id="12-L">0.52</td><td id="12-M">0.42</td><td id="12-N">0.42</td><td id="12-O">0.42</td><td id="12-P">0.512</td><td id="12-Q">0.42</td></tr>
<tr><td id="12-R">Tryptophan (g)</td><td id="12-S">0.16</td><td id="12-T">0.18</td><td id="12-U">0.20</td><td id="12-V">0.20</td><td id="12-W">0.18</td><td id="12-X">0.18</td></tr>
<tr><td id="12-Y">Valine (g)</td><td id="12-Z">0.8</td><td id="12-10">0.58</td><td id="12-11">0.78</td><td id="12-12">0.78</td><td id="12-13">0.673</td><td id="12-14">0.58</td></tr>
</table>

<a id='0230e6ab-8a43-48cb-97fb-2db6be6f4426'></a>

NASPGHAN
FOUNDATION

<a id='2cba4615-2a37-455e-9ea2-78f0e485cb2b'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the dark blue, italicized text "NASPGHAN" on a blue gradient background, with a dark blue curved line underneath.::>

<a id='947c9112-fd40-4922-8ae5-6d24653c3cc4'></a>

Examples of Amino Acid Solutions (per 100 mL)

<a id='272eb963-12ea-4008-b5ab-cf07aa7d220b'></a>

<table id="13-1">
<tr><td id="13-2"></td><td id="13-3">Amino acid</td><td id="13-4">Aminosyn II®</td><td id="13-5">Novamine® 10%</td><td id="13-6">Premasol® 10%</td><td id="13-7">Trophamine® 10%</td><td id="13-8">Aminosyn® PF</td><td id="13-9">Travasol®</td></tr>
<tr><td id="13-a" rowspan="5">Nonsessential</td><td id="13-b">Aspartic Acid (g)</td><td id="13-c"></td><td id="13-d"></td><td id="13-e">0.32</td><td id="13-f">0.32</td><td id="13-g">0.527</td><td id="13-h">–</td></tr>
<tr><td id="13-i">Serine (g)</td><td id="13-j">0.42</td><td id="13-k">0.50</td><td id="13-l">0.38</td><td id="13-m">0.38</td><td id="13-n">0.495</td><td id="13-o">0.50</td></tr>
<tr><td id="13-p">Glutamic Acid (g)</td><td id="13-q"></td><td id="13-r"></td><td id="13-s">0.50</td><td id="13-t">0.50</td><td id="13-u">0.82</td><td id="13-v">–</td></tr>
<tr><td id="13-w">Alanine (g)</td><td id="13-x">1.28</td><td id="13-y">2.07</td><td id="13-z">0.54</td><td id="13-A">0.54</td><td id="13-B">0.698</td><td id="13-C">2.07</td></tr>
<tr><td id="13-D">Proline (g)</td><td id="13-E">0.86</td><td id="13-F">0.68</td><td id="13-G">0.68</td><td id="13-H">0.68</td><td id="13-I">0.812</td><td id="13-J">0.68</td></tr>
<tr><td id="13-K" rowspan="7">Conditionally Essential</td><td id="13-L">Arginine (g)</td><td id="13-M">0.98</td><td id="13-N">1.15</td><td id="13-O">1.2</td><td id="13-P">1.2</td><td id="13-Q">1.227</td><td id="13-R">1.15</td></tr>
<tr><td id="13-S">Glycine (g)</td><td id="13-T">1.28</td><td id="13-U">1.03</td><td id="13-V">0.36</td><td id="13-W">0.36</td><td id="13-X">0.385</td><td id="13-Y">1.03</td></tr>
<tr><td id="13-Z">Glutamine (g)</td><td id="13-10"></td><td id="13-11"></td><td id="13-12">0.50</td><td id="13-13">0.50</td><td id="13-14"></td><td id="13-15"></td></tr>
<tr><td id="13-16">Taurine (g)</td><td id="13-17"></td><td id="13-18"></td><td id="13-19">0.025</td><td id="13-1a">0.025</td><td id="13-1b">0.070</td><td id="13-1c"></td></tr>
<tr><td id="13-1d">Cysteine (g)</td><td id="13-1e"></td><td id="13-1f"></td><td id="13-1g">< 0.016</td><td id="13-1h">< 0.016</td><td id="13-1i">- (dash symbol)</td><td id="13-1j">- (dash symbol)</td></tr>
<tr><td id="13-1k">Histidine (g)</td><td id="13-1l">0.3</td><td id="13-1m">0.48</td><td id="13-1n">0.48</td><td id="13-1o">0.48</td><td id="13-1p">0.31</td><td id="13-1q">0.48</td></tr>
<tr><td id="13-1r">Tyrosine (g)</td><td id="13-1s">0.444</td><td id="13-1t">0.04</td><td id="13-1u">0.24</td><td id="13-1v">0.24</td><td id="13-1w">0.044</td><td id="13-1x">0.04</td></tr>
</table>

<a id='1fed04b4-c6e9-4008-b11b-c52872bb1386'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='e16a5622-2816-4efb-bda4-13314015d512'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the dark blue text "NASPGHAN" on a light blue gradient background, with a dark blue curved line beneath the text.::>

<a id='bc5b7f84-4a24-4ae9-85a2-120246d9bff5'></a>

# Conditions With Altered Protein Needs

*   Increased protein needs (from RDA)
    *   Malnutrition
    *   Enteric/urinary protein losses
    *   Physiologic stress
    *   Drugs (i.e., corticosteroids)
    *   Burns

<a id='167388be-7846-4303-b524-a48c92672a6a'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='89a15fa4-fab7-4d2a-b568-f56586f0ea14'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the word "NASPGHAN" in dark blue text on a blue gradient background, with a subtle curved line beneath the text.::>

<a id='0237cc1a-1f74-459f-8e15-fc808e1f2fe1'></a>

Macronutrients: Intravenous Fat Emulsions (ILE)

<a id='a1554fcc-1fa5-4ed3-91b2-39bc266b6f04'></a>

* Fats
  * Concentrated source of calories
  * Meets essential fatty acid needs
* Multiple lipid solutions available providing triglycerides derived from different oils

<a id='8fb3c405-b9e9-4cb4-935f-03674fce6837'></a>

* Essential fatty acid (EFA) needs: 1-4% calories (minimum) must come from a combination of linoleic and linolenic acid to meet EFA needs
  * Serum triene:tetraene ratio > 0.2 reflects EFA deficiency
  * Ratio may not accurately reflect EFA deficiency if both EFAs low

<a id='73a45254-d08f-4608-84db-05177b9fb9e0'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='520f627f-fb8c-4933-bd02-c5068dc49495'></a>

Wolfram G, et al. J Parenter Enteral Nutr. 1978;2(5):634-9.

<a id='29b45539-17a3-43ca-9da4-9715a33e1517'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the dark blue, italicized text "NASPGHAN" on a blue gradient background, with a sweeping dark blue curved line underneath.::>

<a id='fa8b5476-0b1b-4df7-8ff0-b1d56918ff12'></a>

## Macronutrients: ILE – Cont'd

* Fats are infused over 24 hours to maximize tolerance
  * Monitor triglycerides to assess tolerance
  * Neonates: triglyceride levels <200 mg/dL
  * Children: triglyceride levels <300-400 mg/dL

<a id='29e8a447-6d8c-449a-a50a-b2e4b8298cd9'></a>

- Fat decreases the osmolality of the PN solution
- More concentrated form of calories compared to dextrose and amino acids

<a id='481eaa25-61f7-43c6-9e32-19cf913fd0e1'></a>

NASPGHAN
FOUNDATION

<a id='f08ddef4-59be-4f0c-8b8a-8439229329b2'></a>

Wolfram G, et al. J Parenter Enteral Nutr. 1978;2(5):634-9.

<a id='6245d409-9af3-4a5d-96c4-62d9f4154e2c'></a>

CAPTION ERROR

<a id='b26e8c3c-7d25-41ed-9ec1-b9aa8cbd1b44'></a>

Macronutrients: Comparison of ILE

<a id='bedaa4ac-1092-401c-928a-009eaa67614d'></a>

<table id="17-1">
<tr><td id="17-2">Component</td><td id="17-3">Intralipid®</td><td id="17-4">Omegaven®</td><td id="17-5">ClinoLipid® / ClinOleic®</td><td id="17-6">SMOFLipid®</td></tr>
<tr><td id="17-7">Soybean oil, %</td><td id="17-8">100</td><td id="17-9"></td><td id="17-a">20</td><td id="17-b">30</td></tr>
<tr><td id="17-c">Medium-chain triglycerides, %</td><td id="17-d"></td><td id="17-e"></td><td id="17-f"></td><td id="17-g">30</td></tr>
<tr><td id="17-h">Olive oil, %</td><td id="17-i"></td><td id="17-j"></td><td id="17-k">80</td><td id="17-l">25</td></tr>
<tr><td id="17-m">Fish oil, %</td><td id="17-n"></td><td id="17-o">100</td><td id="17-p"></td><td id="17-q">15</td></tr>
<tr><td id="17-r">Glycerol, g/100 mL</td><td id="17-s">2.25</td><td id="17-t">2.5</td><td id="17-u">2.25</td><td id="17-v">2.5</td></tr>
<tr><td id="17-w">Egg phospholipid, g/10 mL</td><td id="17-x">1.2</td><td id="17-y">1.2</td><td id="17-z">1.2</td><td id="17-A">1.2</td></tr>
<tr><td id="17-B">Phytosterols, mg/100 ml</td><td id="17-C">439  5.7</td><td id="17-D">3.66</td><td id="17-E">274  2.6</td><td id="17-F">207</td></tr>
<tr><td id="17-G">Vitamin E, mg/100 mL</td><td id="17-H">3.8</td><td id="17-I">15 - 30</td><td id="17-J">3.2</td><td id="17-K">16 - 23</td></tr>
<tr><td id="17-L">LA, %</td><td id="17-M">50</td><td id="17-N">4.4</td><td id="17-O">18.5</td><td id="17-P">21.4</td></tr>
<tr><td id="17-Q">ALA, %</td><td id="17-R">9</td><td id="17-S">1.8</td><td id="17-T">2</td><td id="17-U">2.5</td></tr>
<tr><td id="17-V">EPA, %</td><td id="17-W">0</td><td id="17-X">19.2</td><td id="17-Y">0</td><td id="17-Z">3</td></tr>
<tr><td id="17-10">DHA, %</td><td id="17-11">0</td><td id="17-12">12.1</td><td id="17-13">0</td><td id="17-14">2</td></tr>
<tr><td id="17-15">ARA, %</td><td id="17-16">0</td><td id="17-17">1 - 4</td><td id="17-18">0</td><td id="17-19">0.15 - 0.6</td></tr>
</table>

<a id='d8bd26cb-c184-4248-8a7e-8237bcc83fb8'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='1e19295e-6f19-404d-b41d-93653a92a696'></a>

CAPTION ERROR

<a id='92123a78-9131-45bb-a02f-874a9780d3bf'></a>

CAPTION ERROR

<a id='0fe70127-4c9b-42ce-9272-05fe9619ba74'></a>

# Micronutrients Overview

* General principle: monitor regularly and adjust in PN if needed
* Maintain homeostasis
* Weight-based supplementation appropriate starting point
* Alterations may be necessary by disease states
  * Neonatal period
  * Critical illness
  * Renal disease
  * Liver disease

<a id='14db42d8-eb56-4a77-8ec5-9392140c665e'></a>

<::transcription of the content
: NASPGHAN FOUNDATION logo::>

<a id='8de801db-0eac-469f-a5e5-0be3d59d03bd'></a>

Corkins MR, et al. The A.S.P.E.N. Pediatric Nutrition Support Core Curriculum, 2nd Ed. ASPEN;2015.
Denne SC. Semin Neonatol. 2001;6(5):377-82.

<a id='80a3a73c-1621-425d-aa11-a87024486210'></a>

CAPTION ERROR

<a id='b2295a52-fb70-4fcb-907c-acc880975ab9'></a>

Micronutrients Overview – Cont'd

<a id='ff97bdef-35e7-4fd5-914c-2ed0280cdec3'></a>

# Sodium
* Consider acid-base balance, fluids & diuretic therapy

<a id='a07709ac-e8af-45f9-b22c-3f7aaf3281d1'></a>

Potassium
* Consider renal function, diuretic therapy, gastrointestinal losses, medication interactions (including insulin), sodium in PN, dextrose administration

<a id='b8dfec4a-1822-4d7b-81ca-ec96c8358cbc'></a>

Calcium
* Consider phosphate levels, bone health, serum albumin level

<a id='e8ba5463-432a-4aa3-9526-e9192a63d64c'></a>

Phosphate
* Consider ionized calcium levels, renal function, bone health
* Calcium and phosphate requirements higher in preterm infants

<a id='b7d2a236-a186-43e6-bb8a-d9ca6f62b96c'></a>

Magnesium
* Consider potassium, calcium, phosphate levels, renal losses, gastrointestinal losses, bone health, medication interactions (including PPI therapy), clinical signs and symptoms

<a id='938338e8-cf57-42fd-a565-0e9611bac6cb'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='5e5878af-e176-4fee-9b0c-14f27b6b4749'></a>

Corkins MR, et al. The A.S.P.E.N. Pediatric Nutrition Support Core Curriculum, 2nd Ed. ASPEN;2015.
Denne SC. Semin Neonatol. 2001;6(5):377-82.

<a id='257bdd82-3407-4dc3-a7f5-c58677f6cdb2'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the text "NASPGHAN" in dark blue, italicized, on a blue gradient background, with a curved dark blue line underneath the text.::>

<a id='486d5ba3-2f0a-41af-9933-e312c01d295c'></a>

Electrolyte and Mineral Requirements

<a id='d01c3b8b-0f42-42e1-a426-b7977b338fde'></a>

<table id="20-1">
<tr><td id="20-2"></td><td id="20-3">Preterm Neonates</td><td id="20-4">Infants / Children</td><td id="20-5">Adolescents / Children > 40 kg</td></tr>
<tr><td id="20-6">Sodium (mEq/kg/day)</td><td id="20-7">2 - 5</td><td id="20-8">2 - 5</td><td id="20-9">80 - 150 mEq/day</td></tr>
<tr><td id="20-a">Potassium (mEq/kg/day)</td><td id="20-b">2 - 4</td><td id="20-c">2 - 4</td><td id="20-d">40 - 60 mEq/day</td></tr>
<tr><td id="20-e">Calcium (mEq/kg/day)</td><td id="20-f">2 - 4</td><td id="20-g">0.5 - 4</td><td id="20-h">10 - 20 mEq/day</td></tr>
<tr><td id="20-i">Phosphorus (nmol/kg/day)</td><td id="20-j">1 - 2</td><td id="20-k">0.5 - 2</td><td id="20-l">10 - 40 mmol/day</td></tr>
<tr><td id="20-m">Magnesium (mEq/kg/day)</td><td id="20-n">0.3 – 0.5</td><td id="20-o">0.3 – 0.5</td><td id="20-p">10 – 30 mEq/day</td></tr>
<tr><td id="20-q">Acetate</td><td id="20-r" colspan="3">As needed to maintain acid-base balance</td></tr>
<tr><td id="20-s">Chloride</td><td id="20-t" colspan="3">As needed to maintain acid-base balance</td></tr>
</table>

<a id='957a4113-ca69-43c2-aa61-b790c603e63a'></a>

<::NASPGHAN FOUNDATION logo with "NASPGHAN" in dark blue/purple and "FOUNDATION" in red/maroon, both bold and slightly italicized, on a blue gradient background.::>

<a id='164276f4-88e9-4dc2-9e64-197811fe5daf'></a>

Corkins MR, et al. The A.S.P.E.N. Pediatric Nutrition Support Core Curriculum, 2nd Ed. ASPEN; 2015.
Denne SC. Semin Neonatol. 2001;6(5):377-82.

<a id='6cfee7b8-5674-435e-ad78-4e3294bf2108'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the text "NASPGHAN" in dark blue, italicized, bold font, set against a rectangular background that transitions from a darker blue at the top to a lighter blue at the bottom, with a dark blue curved line underneath the text.::>

<a id='57eb1e8c-4c97-48e9-946f-89305b066ff2'></a>

Micronutrients: Calcium / Phosphate

<a id='42fa62f2-0b02-48f5-b006-67f4159bd2df'></a>

* Limitations to amounts of calcium and phosphate that may be supplied in PN
  * Calcium and phosphate may precipitate depending on the amounts added to PN solutions
  * Cysteine lowers pH and may be added to neonate/infant PN to increase solubility of Ca and Phosphate

<a id='93dce55b-f466-480c-b850-1459807209d4'></a>

* Factors affecting solubility include
    * Temperature
    * Type of AA product
    * pH of the final solution
    * Lighting
    * Concentration of calcium and phosphate
    * Dextrose concentration
    * Cysteine
    * Order of mixing

<a id='6af82427-6f26-4953-8ca3-2c568f8aed65'></a>

<::NASPGHAN FOUNDATION logo with a blue gradient background::>

<a id='24a32556-d283-41fc-a132-bf2046247975'></a>

Corkins MR, et al. The A.S.P.E.N. Pediatric Nutrition Support Core Curriculum, 2nd Ed. ASPEN;2015.
Denne SC. Semin Neonatol. 2001;6(5):377-82.

<a id='9eafdd54-9402-4794-9589-c90173a9be72'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the dark blue text "NASPGHAN" on a light blue gradient background, with a dark blue curved line sweeping beneath the text.::>

<a id='9d1d8c5a-ecb7-4eec-b55e-4a6aed1c30e1'></a>

Micronutrients: Trace Elements

<a id='9e315063-5ad5-4e0e-9648-530de1432fd3'></a>

- Numerous minerals are integrated into various physiologic functions
- Commercial PN products contain zinc, copper, chromium, manganese
  - Higher amounts of certain trace elements are present in PN solutions due to contamination during manufacturing
- Optimal requirements of trace elements for children are not well understood

<a id='773a2371-99d8-45a9-99f0-b40ba58e4408'></a>

NASPGHAN
FOUNDATION

<a id='1e2200dd-a78a-41a9-b786-6d36ec28d188'></a>

Corkins MR, et al. The A.S.P.E.N. Pediatric Nutrition Support Core Curriculum, 2nd Ed. ASPEN; 2015.
Denne SC. Semin Neonatol. 2001;6(5):377-82.

<a id='fa305877-32d6-4b15-8bc5-c678f801bb73'></a>

CAPTION ERROR

<a id='8198fe1a-f457-4ead-9930-97519d861e8d'></a>

# Micronutrients: Trace Elements – Cont'd

*   In patients with liver disease, copper and manganese doses often need adjustment
    *   Excreted via bile
    *   Levels need to be monitored in patients with cholestasis
*   In patients with renal disease, selenium and chromium need to be used with caution
    *   Levels need to be monitored
*   Manganese can be present as a contaminant in PN solutions
    *   Monitor for manganese toxicity in long-term PN patients
*   Chromium may not be needed in patients on long-term PN

<a id='46444b6a-03e3-41e7-8b6c-c998b305744b'></a>

<::NASPGHAN FOUNDATION logo with a blue gradient background::>

<a id='03c0dcad-9cc8-4964-b7e7-5019e119930a'></a>

Corkins MR, et al. The A.S.P.E.N. Pediatric Nutrition Support Core Curriculum, 2nd Ed. ASPEN;2015.
Denne SC. Semin Neonatol. 2001;6(5):377-82.

<a id='e8d671b4-98a3-444d-8fcd-404d602a813b'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the dark blue, bold, italicized text "NASPGHAN" on a light blue gradient background, with a dark blue curved line sweeping underneath the text from the right.::>

<a id='9e8fd24e-ebed-40da-8f2d-7642a5fe2579'></a>

Components of PN: Trace Elements

<a id='6ddf9165-c3c8-4898-b27b-cccf6eb26ce3'></a>

<table id="24-1">
<tr><td id="24-2">Solution Name</td><td id="24-3">Multrys®</td><td id="24-4">Tralement®</td></tr>
<tr><td id="24-5">Age indication</td><td id="24-6">Neonatal/Pediatric</td><td id="24-7">Pediatric/Adolescent/Adult</td></tr>
<tr><td id="24-8">Weight indication</td><td id="24-9">< 10 kg</td><td id="24-a">≥ 10 kg</td></tr>
<tr><td id="24-b" colspan="3">Trace element in 1 mL solution (mcg)</td></tr>
<tr><td id="24-c">Zinc (Zn)</td><td id="24-d">1,000</td><td id="24-e">3,000</td></tr>
<tr><td id="24-f">Copper (Cu)</td><td id="24-g">50</td><td id="24-h">300</td></tr>
<tr><td id="24-i">Selenium (Se)</td><td id="24-j">6</td><td id="24-k">55</td></tr>
<tr><td id="24-l">Manganese (Mn)</td><td id="24-m">3</td><td id="24-n">60</td></tr>
</table>

<a id='cbc2653e-75e8-4cd9-94ba-be807499e58d'></a>

NASPGHAN
FOUNDATION

<a id='7ed84d5b-5062-41b7-a2ce-a937fab9ff29'></a>

CAPTION ERROR

<a id='b120aac3-b150-48be-810f-bbedafe5e833'></a>

# Micronutrients: Iron (Fe)

*   Iron deficiency is common in PN recipients
    *   Also consider other non-iron deficiency causes of anemia
    *   Consider enteral supplementation over parenteral route for treatment
    *   Addition of Fe to PN requires consideration due to potential increased risk of sepsis (pro-oxidant), and anaphylaxis (FDA black box warning)
*   Consider supplementation in patients who have been NPO
    *   Avoid Fe in patients receiving frequent blood transfusions due to possibility of Fe overload
*   Parenteral Fe preparations
    *   Iron sucrose
    *   Iron dextran
    *   Ferric carboxymaltose (small risk of hypophosphatemia)

<a id='a1d63bfe-1f80-4e5a-b889-2f366887564f'></a>

NASPGHAN
FOUNDATION

<a id='07f5cd2a-3f5d-446a-988f-b5f5ee77de17'></a>

Talathi S, et al. J Pediatr Gastroenterol Nutr. 2023;76(5):672-83.
Khaodhiar L, et al. J Parenter Enteral Nutr. 2002;26(2):114-19.

<a id='8c6ec557-2ca0-40db-aaeb-c65610ccb2a1'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the word "NASPGHAN" in dark blue text on a blue gradient background, with a subtle curved line beneath the text.::>

<a id='b26a8bbc-dfa2-41b9-9704-3a45e10bb676'></a>

# Micronutrients: Zinc (Zn)

*   Important trace element for growth, wound healing
*   Signs of zinc deficiency
    *   Dermatitis, alopecia, diarrhea, immune deficiency
*   Zinc excreted mainly in stool
    *   Increased needs in diarrhea, hypercatabolic states, ostomy losses, intrathoracic/peritoneal drains, mucositis
*   Measures of zinc status
    *   Serum zinc is a poor measure of total body zinc status
    *   Low alkaline phosphatase may be a better marker of zinc deficiency but is not diagnostic
*   May increase PN intake to 1.5 - 2x usual dosing if increased metabolic demand (to maintain one line)
*   Monitor for copper deficiency

<a id='88726970-6c12-4ed7-ba35-e8eaaee44bdf'></a>

<::NASPGHAN
FOUNDATION
: figure::>

<a id='f7c5f6ec-3250-4c50-bad2-b87e7ec4df45'></a>

Corkins MR, et al. The A.S.P.E.N. Pediatric Nutrition Support Core Curriculum, 2nd Ed. ASPEN; 2015.

<a id='86074472-6bdd-4d8b-808d-1bbd9b848615'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the dark blue, bold, and slightly italicized text "NASPGHAN" on a light blue gradient background, with a dark blue curved line swooshing beneath it.::>

<a id='986a60d6-d965-4df6-a370-2ab2b230df1b'></a>

Micronutrients: Copper (Cu)

*   Copper deficiency is rare, except in patients with cholestasis
    *   Risk factors: malabsorption, prematurity, severe malnutrition
    *   May present with anemia (hypochromic, microcytic), leukopenia, neutropenia, bone abnormalities

<a id='6413ae33-d599-4eb9-88bf-c0c3419fcf05'></a>

- Biliary tract is the primary route for Cu excretion
  - Patients with cholestasis have decreased excretion, may be at increased risk for toxicity
  - Note that patients without cholestasis can also have elevated Cu levels

<a id='1e9a8856-47f0-4112-9a15-92acb45ca358'></a>

* Monitor through serum Cu and ceruloplasmin levels
  * Clinical picture should be evaluated to assess Cu status
  * Toxicity may present similarly to Wilson's disease: cirrhosis, neurological disorders, renal damage
  * Deficiency may present similarly to B₁₂ deficiency, with cardiac disease, arthritis, loss of hair pigmentation, neurologic abnormalities, pancytopenia

<a id='3177e1fb-4f69-4a22-9042-29da08f84d27'></a>

<::NASPGHAN FOUNDATION : figure::>

<a id='5ccd0280-dc5b-46ef-a822-e12a8e57779d'></a>

Corkins MR, et al. The A.S.P.E.N. Pediatric Nutrition Support Core Curriculum, 2nd Ed. ASPEN; 2015.

<a id='6e200011-8497-4c90-b97d-d9114cfaea5c'></a>

CAPTION ERROR

<a id='90f277f0-7abe-4d51-94e8-dbf3a130c59d'></a>

Micronutrients: Manganese (Mn)

<a id='b69080f4-c438-41ed-abd3-cfd2ba2e1a19'></a>

* Deficiency very uncommon in humans
* Mn contamination is commonly found through manufacturing of various PN components
* Biliary tract primary route for Mn excretion
  * Patients with cholestasis may have decreased Mn excretion
* Toxicity
  * Symptoms include insomnia, headache, forgetfulness, anxiety, cholestasis, Parkinson's disease-like illness
  * Best assessed through MRI brain (accumulation in basal ganglia)
* Monitoring
  * Regular monitoring of patients receiving chronic PN
  * Erythrocyte or whole-blood Mn concentrations should be measured

<a id='9dd9881b-bf56-45c7-9270-1c11d92afb38'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='f0ce7fc5-11bc-41dd-8cf5-4809437bcc7c'></a>

Corkins MR, et al. The A.S.P.E.N. Pediatric Nutrition Support Core Curriculum, 2nd Ed. ASPEN; 2015.

<a id='183981c8-75f0-4774-8e4c-b3cb6d9da99f'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the dark blue, bold, italicized text "NASPGHAN" on a light blue to white gradient background, with a dark blue curved line sweeping beneath the text.::>

<a id='a0281946-c0b9-4001-a550-b6b3438f6dfd'></a>

# Micronutrients: Selenium (Se)

*   Deficiency may develop within 6 weeks of being Se-free in PN
    *   Can cause cardiomyopathy, growth retardation, pseudo-albinism, white fingernails, hypothyroidism
*   Patients should be supplemented if on exclusive PN for > 4 weeks

<a id='4e8afdff-db71-4b16-9ceb-353bdebdb3d7'></a>

* Toxicity rare
  * May cause nausea, diarrhea, irritability, fatigue, peripheral neuropathy, hair loss, nail changes
  * In patients with impaired renal function, reduce Se from PN

<a id='0ed0473d-64c2-43e3-8050-57a1ac47a687'></a>

* Monitoring
    * Total plasma selenium, glutathione peroxidase, C-reactive protein
    * In presence of systemic inflammation, Se levels may decrease
    * Close monitoring in patients with renal dysfunction

<a id='97d9acbe-0494-4131-a886-a9f41fd232ea'></a>

<::NASPGHAN FOUNDATION logo with a blue gradient background : figure::>

<a id='b18f6f17-fada-4312-bf41-3b3ec64e2230'></a>

Corkins MR, et al. The A.S.P.E.N. Pediatric Nutrition Support Core Curriculum, 2nd Ed. ASPEN; 2015.

<a id='30468647-5fff-4e00-920d-01bd348ed8c1'></a>

CAPTION ERROR

<a id='fd2f742d-c2e4-4ade-b731-dbf0bf72b43d'></a>

# Micronutrients: Chromium (Cr)

*   Excreted in kidneys
*   Common contaminant in PN solutions
    *   Contamination can increase delivery by 10-100%. Deficiency is rare.
*   Chromium deficiency symptoms primarily involve reversible glucose intolerance that does not improve with insulin
*   Monitoring
    *   Close monitoring in patients with renal dysfunction
    *   Consider monitoring both serum Cr concentrations and HbA1C levels regularly in long-term PN patients
    *   Best method for diagnosing Cr deficiency is demonstrating insulin resistance that improves with Cr supplementation, and reappears after supplementation is withdrawn

<a id='30bac5aa-a891-47eb-a6ba-876c3cd5e25d'></a>

<::NASPGHAN FOUNDATION logo with a blue gradient background::>

<a id='754004b3-f2d0-4807-b0f1-170190ef361c'></a>

Corkins MR, et al. The A.S.P.E.N. Pediatric Nutrition Support Core Curriculum, 2nd Ed. ASPEN;2015.

<a id='1375763c-e9e8-4760-a640-e3639a45db0c'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the dark blue, italicized text "NASPGHAN" on a blue gradient background, with a dark blue curved line sweeping beneath the text.::>

<a id='ae985ce0-2f2e-4fba-ad66-ef1e00c4f26b'></a>

Micronutrients:
Multivitamin Vials - Pediatric

<a id='aeba18f5-43cb-4950-a002-00b6d6030257'></a>

Multi-vitamins in PN typically supplied as 2 injectable vials (Vial 1, Vial 2)

<a id='c5c188a6-cf35-4dfd-9b5e-cd0bb9a09630'></a>

<table id="31-1">
<tr><td id="31-2" colspan="2">Infuvite® Pediatric Vial #1 contents (per 4 mL)</td></tr>
<tr><td id="31-3">Active Ingredient</td><td id="31-4">Quantity</td></tr>
<tr><td id="31-5">Ascorbic acid (Vitamin C)</td><td id="31-6">80 mg</td></tr>
<tr><td id="31-7">Vitamin A* (as palmitate)</td><td id="31-8">2,300 IU (equals 0.7 mg)</td></tr>
<tr><td id="31-9">Vitamin D3* (cholecalciferol)</td><td id="31-a">400 IU (equals 10 mcg)</td></tr>
<tr><td id="31-b">Thiamine (Vitamin B1) (as the hydrochloride)</td><td id="31-c">1.2 mg</td></tr>
<tr><td id="31-d">Riboflavin (Vitamin B2) (as riboflavin 5-phosphate sodium)</td><td id="31-e">1.4 mg</td></tr>
<tr><td id="31-f">Pyridoxine HCl (Vitamin B6)</td><td id="31-g">1 mg</td></tr>
<tr><td id="31-h">Niacinamide</td><td id="31-i">17 mg</td></tr>
<tr><td id="31-j">Dexpanthenol (as d-pantothenyl alcohol)</td><td id="31-k">5 mg</td></tr>
<tr><td id="31-l">Vitamin E* (dl-a-tocopheryl acetate)</td><td id="31-m">7 IU (equals 7 mg)</td></tr>
<tr><td id="31-n">Vitamin K₁*</td><td id="31-o">0.2 mg</td></tr>
</table>
*Polysorbate 80 is used to water solubilize the oil-soluble vitamins A, D, E, and K.

<a id='bf9f43a7-27b5-4bd6-ba9d-98c7d6dccfe4'></a>

Infuvite® Pediatric Vial #2 contents
<table id="31-p">
<tr><td id="31-q">Active Ingredient</td><td id="31-r">Quantity</td></tr>
<tr><td id="31-s">Folic acid</td><td id="31-t">140 mcg</td></tr>
<tr><td id="31-u">Biotin</td><td id="31-v">20 mcg</td></tr>
<tr><td id="31-w">Vitamin B12 (cyanocobalamin)</td><td id="31-x">1 mcg</td></tr>
</table>

<a id='adb753c3-a379-48ce-8c5b-02f665858bb7'></a>

NASPGHAN
FOUNDATION

<a id='faf4b54e-4d89-4709-97c3-049ebedd173e'></a>

U.S. Food and Drug Administration. "FDA Online Label Repository."
Accessed September 19, 2024. https://labels.fda.gov/.

<a id='edeb6f17-40fe-467f-8c12-7c2becdb833a'></a>

CAPTION ERROR

<a id='81cad6a7-8880-4246-b383-9b20868ba472'></a>

Micronutrients:
Multivitamin Vials - Adult

<a id='043ae497-683d-49ba-9fb6-0e07481ea0a7'></a>

Multi-vitamins in PN typically supplied as 2 injectable vials
(Vial 1, Vial 2; note differences in dosing and volume)

<a id='9334bffd-f432-4ea7-b34c-73387358b183'></a>

Infuvite® Adult Vial #1 contents (per 5 mL)

Ascorbic acid (Vitamin C) ... 200 mg
Vitamin A* (as palmitate) ... 3,300 IU
Vitamin D3* (cholecalciferol) ... 200 IU
Thiamine (Vitamin B1) (as the hydrochloride) ... 6 mg
Riboflavin (Vitamin B2)
(as riboflavin 5-phosphate sodium) ... 3.6 mg
Pyridoxine HCl (Vitamin B6) ... 6 mg
Niacinamide ... 40 mg
Dexpanthenol
(as d-pantothenyl alcohol) ... 15 mg
Vitamin E* (dl-α-tocopheryl acetate) ... 10 IU
Vitamin K1* ... 150 mcg

<a id='f7feee00-ed91-4144-8ecd-9e23accf7446'></a>

Infuvite® Adult Vial #2 contents (per 5 mL)
Folic acid ... 600 mcg
Biotin ... 60 mcg
Vitamin B12 (cyanocobalamin) ... 5 mcg

<a id='acab63f1-4d29-4e3b-8db5-c9ac3913d150'></a>

<::NASPGHAN FOUNDATION
: figure::>

<a id='887b93a8-d152-4191-9e4c-e9c4be00139d'></a>

U.S. Food and Drug Administration. "FDA Online Label Repository."
Accessed September 19, 2024. https://labels.fda.gov/.

<a id='e6b3b629-a7b3-4cc6-a589-7fc4f60ff41a'></a>

CAPTION ERROR

<a id='3859fa97-21bb-4e26-8e86-b62922d22b35'></a>

# Acid Base / Balance

* May be managed by addition or removal of sodium, potassium acetate
  * Acetate = bicarbonate precursor
* Bicarbonate contraindicated in PN
  * Calcium / phosphate precipitation
  * High Na load
  * Generates CO2 in PN bag

<a id='19ce6a77-dd35-402d-b499-08a2bd14ab3f'></a>

NASPGHAN
FOUNDATION

<a id='da465991-6b0a-42dd-8d44-95af2741f8e8'></a>

Corkins MR, et al. The A.S.P.E.N. Pediatric Nutrition Support Core Curriculum, 2nd Ed. ASPEN; 2015.

<a id='0304c69d-99e5-441e-837a-d4ab21c2ee53'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features dark blue, bold, italicized text "NASPGHAN" on a blue gradient background, with a dark blue curved swoosh underneath.::>

<a id='a204feca-9c26-4dc8-a860-56f343a8d9c5'></a>

Heparin

* Prophylactic anticoagulant used to prevent thrombosis
* Reduces formation of fibrin sheath around catheter
  * May reduce phlebitis with peripheral IV access
  * May facilitate lipid clearance (increases lipolysis and releases free fatty acids)

<a id='988da9c5-9dca-4a10-9de2-9834cf68275a'></a>

* Heparin dosing
  * 1 unit/mL full-term infants to adults
  * 0.5 units/mL preterm and VLBW infants (< 1500 g)

<a id='8f4438c4-2af9-4535-8bc1-8f8ec4cbff04'></a>

<::transcription of the content
: NASPGHAN
FOUNDATION
: logo::>

<a id='c8140581-83bf-4e6d-a3c8-85dbcd7a5b06'></a>

Corkins MR, et al. The A.S.P.E.N. Pediatric Nutrition Support Core Curriculum, 2nd Ed. ASPEN; 2015.

<a id='0f5f351e-85a5-4c9d-b01e-3460eeed2d55'></a>

<::logo: NASPGHAN
NASPGHAN
The logo features the text "NASPGHAN" in dark blue, set against a light blue rectangular background with a gradient fading to white at the bottom, with a dark blue curved line sweeping underneath the text.::>

<a id='94405044-ce90-4b85-b29a-ccf72f3482e7'></a>

## Case: Review

*   Jerry is a previously healthy 13-year-old male. He was transferred from an outside hospital after undergoing exploratory laparotomy for a complicated perforated appendicitis. Due to extensive lysis of adhesions and inflamed bowel, the decision was made to create an ileostomy 100 cm distal to the ligament of Treitz.
*   Since surgery he has been having 75 - 100 mL/kg of ostomy output daily. He will be NPO for at least 1 week while receiving IV antibiotics for his intra-abdominal infection secondary to intestinal perforation.

**Question: What is the most appropriate way to provide adequate hydration and nutrition to GE?**

<a id='554dfafb-d41b-4ec5-b245-d3679262df24'></a>

NASPGHAN
FOUNDATION

<a id='4954c802-cd7a-42b6-bcf4-2d5e7217086b'></a>

CAPTION ERROR

<a id='9c5e2ee1-0251-4446-aa90-d569e64e130e'></a>

# Case: Review

* Jerry is a previously healthy 13-year-old male. He was transferred from an [illegible]
* GE was initiated on PN through a tunneled central line with an initial caloric delivery of 1700 kcal
* 3 months after initial ostomy creation, ostomy was taken down and intestines placed in continuity
* PN weaned inpatient over 14 days after ostomy take down
* He continues to require micronutrient supplementation (B12, Zn), but eats a regular diet by mouth and has no activity restrictions
* [illegible] antibiotics for his intra-abdominal infection secondary to intestinal perforation.

<a id='bcdf71a7-a972-4b12-900c-ad6753e8e142'></a>

Question: What is the most appropriate way to provide adequate hydration and nutrition to GE?

<a id='52a3678b-da9e-4b3d-a8de-5906cd48bc24'></a>

<::NASPGHAN FOUNDATION logo with a blue gradient background: figure::>

<a id='91c5f98e-54fb-4dcc-a68c-2e1dfdf6cdf0'></a>

CAPTION ERROR